Not all neoantigens predicted from the algorithms with a different binding affinity between WT and MT peptides showed good immunogenic [44]; hence, the cancer cell-killing activity of the activated T cells is the key function supported by the increasing IFN-γ- and CD107a-producing T cells from neoantigen peptide stimulation and their cancer cell-killing activity [41, 45]. Here, LAMP1 is linked to cancer.